SCHEMBL24173293

SCHEMBL24173293

O=C(Cc1cccc(F)c1Cl)Nc1ccncc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.67
▸ ANO1 Q5XXA6 1/20 0.60
▸ DNMT3B Q9UBC3 1/20 0.54
▸ RAB9A P51151 4/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ JAK2 O60674 4/20 0.53
▸ JAK1 P23458 3/20 0.53
▸ TYK2 P29597 3/20 0.53
▸ HTT P42858 2/20 0.52
▸ NOD2 Q9HC29 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ KMT2A Q03164 2/20 0.50
▸ TSHR P16473 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ P2RX4 Q99571 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ KCNJ5 P48544 1/20 0.48
▸ KCNJ3 P48549 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ PRKACA P17612 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30368144 0.83 TYK2 (0.56) SMN1; SMN2ANO1RAB9ANPC1TYK2
SCHEMBL30367890 0.81 SMN1; SMN2 (0.57) SMN1; SMN2ANO1DNMT3BRAB9ANPC1
SCHEMBL30402922 0.81 ANO1 (0.61) SMN1; SMN2ANO1RAB9ANPC1ALDH1A1
SCHEMBL5639552 0.81 SMN1; SMN2 (0.81) SMN1; SMN2DNMT3BRAB9ANPC1JAK2
SCHEMBL24173209 0.81 SMN1; SMN2 (1.00) SMN1; SMN2DNMT3BRAB9ANPC1JAK2
SCHEMBL30502369 0.80 KCNJ5 (0.68) SMN1; SMN2ANO1RAB9ANPC1JAK2
SCHEMBL30368210 0.80 ANO1 (0.65) SMN1; SMN2ANO1JAK2JAK1TYK2
SCHEMBL30285596 0.78 ALDH1A1 (0.53) SMN1; SMN2ANO1RAB9ANPC1ALDH1A1
SCHEMBL26186439 0.78 ALDH1A1 (0.53) SMN1; SMN2ANO1RAB9ANPC1ALDH1A1
SCHEMBL30285772 0.78 ANO1 (0.60) SMN1; SMN2ANO1RAB9ANPC1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4171744-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS Bayer Aktiengesellschaft (DE) 2023-05-03 — — EP claimed
EP-4172146-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY Bayer Aktiengesellschaft (DE) 2023-05-03 — — EP claimed
WO-2022002860-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2022-01-06 — — WO disclosed
WO-2022002859-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2022-01-06 — — WO disclosed
Send feedback